Vpriv velaglucerase alfa: Interim expanded access program data

An interim safety analysis of >150 patients in the ongoing, open-label, U.S. HGT-GCB-058 treatment protocol implemented to provide expanded access of Vpriv to patients affected by the shortage of Cerezyme imiglucerase showed that 18% of patients previously treated with Cerezyme experienced a treatment-emergent adverse event that Shire said was "possibly or probably related" to Vpriv. The most common treatment-emergent adverse events among patients who switched from Cerezyme to Vpriv included nasopharyngitis, nausea, fatigue, headache, dizziness, influenza and infusion-related reactions. ...